Blog
Valuable TargetsAdvanced Tech.
Recent blog posts
Floretyrosine F18 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Floretyrosine F18 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Floretyrosine F18: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Adrabetadex Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Adrabetadex Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Adrabetadex: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Zilurgisertib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Zilurgisertib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Zilurgisertib: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Valsartan/Levamlodipine Maleate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Valsartan/Levamlodipine Maleate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Valsartan/Levamlodipine Maleate: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Pritelivir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Pritelivir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Pritelivir: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Neladalkib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Neladalkib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Neladalkib: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Pumecitinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Pumecitinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Pumecitinib: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Rexlemestrocel-L Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Rexlemestrocel-L Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Rexlemestrocel-L: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Lorecivivint Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Lorecivivint Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Lorecivivint: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Encaleret sulfate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Encaleret sulfate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Encaleret sulfate: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Velinotamig Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Velinotamig Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Velinotamig: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Zandelisib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Zandelisib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Zandelisib: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →